Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PABLO F MORA

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1306836168
CMS profile
149702
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$77,886.46

180 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PABLO F MORA

NPI 1306836168 · CMS profile ID 149702

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306836168?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PABLO F MORA, NPI 1306836168, CMS profile ID 149702. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306836168?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). PABLO F MORA, NPI 1306836168, CMS profile ID 149702. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306836168?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
PABLO F MORA, NPI 1306836168, CMS profile ID 149702, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1306836168?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

180 matching records · $77,886.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 180 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 180.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mannkind Corporation $5.3810/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752675941 CMS
Novo Nordisk Inc $20.0010/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744943865 CMS
Mannkind Corporation $17.6310/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752675939 CMS
Dexcom, Inc. $8.3410/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752068993 CMS
Novo Nordisk Inc $311.1010/05/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745066175 CMS
Novo Nordisk Inc $48.6809/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744992053 CMS
Novo Nordisk Inc $2,379.0009/30/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744992055 CMS
Dexcom, Inc. $1,200.0009/24/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752068991 CMS
Novo Nordisk Inc $8.6209/24/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744992051 CMS
Dexcom, Inc. $7.2009/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752068989 CMS
Mannkind Corporation $10.1109/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752675937 CMS
Novo Nordisk Inc $6.2909/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744886685 CMS
AstraZeneca Pharmaceuticals LP $23.2009/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736203147 CMS
Amarin Pharma Inc. $21.3309/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739979963 CMS
AstraZeneca Pharmaceuticals LP $22.8009/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735786445 CMS
Xeris Pharmaceuticals, Inc. $19.4708/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739716355 CMS
Novo Nordisk Inc $1,262.7008/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744879409 CMS
Novo Nordisk Inc $1,683.6008/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744879419 CMS
Mannkind Corporation $22.1108/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752675935 CMS
Amarin Pharma Inc. $6.6308/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739993483 CMS
Mannkind Corporation $9.9308/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752675933 CMS
Novo Nordisk Inc $1,830.0008/19/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744979623 CMS
Novo Nordisk Inc $17.4708/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744842313 CMS
Novo Nordisk Inc $0.8608/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744842315 CMS
Novo Nordisk Inc $1,830.0008/18/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744974801 CMS
Novo Nordisk Inc $1,830.0008/18/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744976493 CMS
Novo Nordisk Inc $1,830.0008/18/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744978359 CMS
Novo Nordisk Inc $2,379.0008/18/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744979501 CMS
Novo Nordisk Inc $116.0408/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744979503 CMS
Novo Nordisk Inc $29.3808/18/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744979517 CMS
Novo Nordisk Inc $1,830.0008/18/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744991453 CMS
Novo Nordisk Inc $1,830.0008/14/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745055027 CMS
Lilly USA, LLC $12.6908/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728598023 CMS
Novo Nordisk Inc $1,830.0008/13/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744878779 CMS
Merck Sharp & Dohme Corporation $15.2708/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747691411 CMS
Dexcom, Inc. $1,200.0008/06/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752068987 CMS
Novo Nordisk Inc $22.8608/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744825277 CMS
Mannkind Corporation $9.3307/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752675931 CMS
Xeris Pharmaceuticals, Inc. $23.7907/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739716353 CMS
Mannkind Corporation $5.6407/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752675927 CMS
Mannkind Corporation $14.0907/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752675929 CMS
Novo Nordisk Inc $13.7907/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744797099 CMS
Mannkind Corporation $7.0607/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752675925 CMS
AstraZeneca Pharmaceuticals LP $16.6007/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736152879 CMS
Merck Sharp & Dohme Corporation $20.2507/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747716811 CMS
Novo Nordisk Inc $1,830.0007/09/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744878239 CMS
Novo Nordisk Inc $15.5507/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744780551 CMS
Amarin Pharma Inc. $19.6007/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739993481 CMS
Dexcom, Inc. $11.9407/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752068985 CMS
Mannkind Corporation $1,125.0006/29/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752675923 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $336,171.95 439
PY2020 $77,886.46 180
PY2021 $131,164.06 266
PY2022 $122,305.63 285
PY2023 $167,923.03 321
PY2024 $223,720.27 381
PY2025 $276,491.08 492

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $366,051.79 23
PY2024 Recipient $1,563.06 11
PY2024 Principal investigator $153,239.24 24
PY2023 Principal investigator $6,859.80 2
PY2020 Recipient $145.50 1
PY2020 Principal investigator $107,900.03 116
PY2019 Recipient $8,403.48 4
PY2019 Principal investigator $169,054.20 51

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
TEKTON RESEARCH
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202534639
Principal investigator 1 ABBVIE INC. $5,814.45 12/31/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202535387
Principal investigator 1 ABBVIE INC. $19,448.10 11/05/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522201
Principal investigator 1 ABBVIE INC. $16,580.70 10/09/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515339
Principal investigator 1 ABBVIE INC. $14,380.20 09/04/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509138
Principal investigator 1 ABBVIE INC. $18,909.45 08/06/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503069
Principal investigator 1 Amgen Inc. $8,025.84 08/01/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246649065
Principal investigator 1 ABBVIE INC. $395.80 07/31/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202500570
Principal investigator 1 ABBVIE INC. $16,046.10 07/02/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494141
Principal investigator 1 SANOFI US SERVICES INC. $23,689.00 07/02/2025 Non-covered Recipient Entity
Tekton Research Inc
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF and Anti-OX40L NANOBODY Molecule, for Preservation of Pancreatic B-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes No dispute reported 06/30/2026 1226108276
Principal investigator 1 Medtronic, Inc. $1,560.00 06/24/2025 Non-covered Recipient Entity
Tekton Research
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327470
Principal investigator 1 Medtronic, Inc. $3,500.00 06/17/2025 Non-covered Recipient Entity
Tekton Research
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327468
Principal investigator 1 ABBVIE INC. $27,603.45 06/03/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488735
Principal investigator 1 Medtronic, Inc. $5,000.00 05/23/2025 Non-covered Recipient Entity
Tekton Research
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327466
Principal investigator 1 ABBVIE INC. $19,866.60 05/07/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483815
Principal investigator 1 Eli Lilly and Company $127,380.00 04/08/2025 Non-covered Recipient Entity
TEKTON RESEARCH INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-1) No dispute reported 06/30/2026 1187890108
Principal investigator 1 ABBVIE INC. $10,597.50 04/03/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202472819
Principal investigator 1 ABBVIE INC. $12,309.30 03/07/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459134
Principal investigator 1 Amgen Inc. $13,464.70 02/25/2025 Non-covered Recipient Entity
TEKTON RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246649100
Principal investigator 1 Medtronic, Inc. $438.00 02/21/2025 Non-covered Recipient Entity
Tekton Research
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327464
Principal investigator 1 Medtronic, Inc. $57.00 02/11/2025 Non-covered Recipient Entity
Tekton Research
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327462
Principal investigator 1 ABBVIE INC. $14,385.60 02/06/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202448612
Principal investigator 1 ABBVIE INC. $1,080.00 01/02/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202435031